Janux Therapeutics, Inc. 8-K

What Happened
Janux Therapeutics, Inc. announced in an 8‑K (Item 8.01) dated June 23, 2026, that William Go, M.D., Ph.D., has departed his role as Chief Medical Officer. The company determined the departure to constitute a termination without “Cause” under its Change in Control and Severance Benefit Plan. Janux said Dr. Go’s exit was not due to any disagreement with the company on operations, policies, or practices, and that existing clinical leadership will assume his responsibilities while the company searches for a successor. The company stated the transition does not affect its development strategy, regulatory plans, or previously disclosed clinical timelines.

Key Details

• Date of filing/event: June 23, 2026 (Form 8‑K, Item 8.01).
• Executive: William Go, M.D., Ph.D., Chief Medical Officer — departed effective June 23, 2026.
• Company determination: Classified as a termination without “Cause” under the Company’s Change in Control and Severance Benefit Plan (plan filed as Exhibit 10.12 to Janux’s Form S‑1 filed May 19, 2021).
• Interim plan: Current clinical leadership will cover Dr. Go’s duties while a successor search is underway; company says no change to development or clinical timelines.

Why It Matters
For investors, the key takeaways are that Janux experienced an executive change at the CMO level but characterizes the departure as orderly (no disagreement) and says its clinical and regulatory programs are unaffected. Because the company classified the departure as a termination without “Cause” under its severance plan, the event may trigger contractual severance obligations under that plan (the filing does not disclose any payment amounts). Investors should note management continuity risks at the clinical leadership level but also the company’s explicit statement that disclosed development timelines remain unchanged.